Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6559305 | PFIZER | Linezolid—crystal form II |
Jan, 2021
(3 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5688792 | PFIZER | Substituted oxazine and thiazine oxazolidinone antimicrobials |
Nov, 2014
(9 years ago) | |
US5688792 (Pediatric) | PFIZER | Substituted oxazine and thiazine oxazolidinone antimicrobials |
May, 2015
(8 years ago) | |
US6559305 | PFIZER | Linezolid—crystal form II |
Jan, 2021
(3 years ago) | |
US6514529 | PFIZER | Oxazolidinone tablet formulation |
Mar, 2021
(3 years ago) | |
US6559305 (Pediatric) | PFIZER | Linezolid—crystal form II |
Jul, 2021
(2 years ago) | |
US6514529 (Pediatric) | PFIZER | Oxazolidinone tablet formulation |
Sep, 2021
(2 years ago) |
Market Authorisation Date: 18 April, 2000
Treatment: Treatment of microbial infections
Dosage: SOLUTION;INTRAVENOUS; FOR SUSPENSION;ORAL; TABLET;ORAL